Lamivudina E Zidovudina Mylan (Zidovudine, Lamivudine)

Zidovudine is a nucleoside analogue that, after cellular phosphorylation, mimics the natural building blocks of viral DNA. When incorporated by HIV reverse transcriptase, it terminates the growing DNA chain, halting viral replication. Lamivudine works through a similar mechanism, providing a synergistic effect.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, disease stage, and other medications. Healthcare providers follow established guidelines and adjust therapy as needed.

Zidovudine/lamivudine is classified as Pregnancy Category C, meaning risk cannot be ruled out. It may be used when the potential benefits justify the risks. Breastfeeding decisions should be made with a healthcare professional, weighing maternal benefits against possible infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Zidovudine/lamivudine offers a well‑studied, dual‑nucleoside regimen with proven efficacy. Compared with newer integrase inhibitors, it may have a different side‑effect profile, such as higher rates of anemia, but remains a cost‑effective option in many treatment guidelines.

Store the tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture and direct sunlight to maintain stability throughout the shelf life.

The medication is taken orally, usually with food or a glass of water, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include severe lactic acidosis, hepatic steatosis, and bone‑marrow suppression leading to anemia or neutropenia. Patients should be monitored regularly for signs of metabolic disturbances, liver dysfunction, and blood‑cell abnormalities.

Individuals with known hypersensitivity to zidovudine, lamivudine, or any excipients should avoid the product. Caution is also advised for patients with severe liver disease, pre‑existing bone‑marrow disorders, or those receiving contraindicated drug combinations.